Chemistry:Licogliflozin
From HandWiki
Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity,[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis.[2][3]
References
- ↑ "Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials". Diabetes & Metabolic Syndrome 16 (11): 102657. November 2022. doi:10.1016/j.dsx.2022.102657. PMID 36335885.
- ↑ "Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial". Diabetes, Obesity & Metabolism 23 (11): 2595–2599. November 2021. doi:10.1111/dom.14495. PMID 34263971.
- ↑ "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study". Nature Medicine 28 (7): 1432–1438. July 2022. doi:10.1038/s41591-022-01861-9. PMID 35725922.
 |  |
